This week brought more bad news for the makers of Avastin – a top-selling cancer drug that has become embroiled in controversy. U.S. researchers released a study showing that women with advanced breast cancer who were treated with Avastin were more likely to develop heart failure than patients not given the therapy.
The findings, published in the Journal of Clinical Oncology, come on the heels of earlier studies that suggest the drug is ineffective and potentially unsafe.
Health regulators in the United States and Europe have expressed mixed opinions about whether use of the drug should be curtailed. Health Canada is currently “reviewing the evidence.” In Canada, Avastin is sold by Hoffmann-La Roche Ltd.